Risk factors for pancreatogenic diabetes after pancreaticoduodenectomy

Hyoung Min Oh, Yoo-Seok Yoon, Ho-Seong Han, Ji Hoon Kim, Jai Young Cho, and Dae-Wook Hwang

Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea

Backgrounds/Aims: Postoperative diabetes mellitus (DM) after pancreaticoduodenectomy (PD) may compromise the long-term quality of life in survivors after the operative procedure due to the treatment difficulty and its related complications. The aim of this study is to determine the incidence of new-onset pancreatogenic DM after PD and investigate the risk factors for this complication. Methods: Among 170 patients who had undergone PD between November 2003 and September 2009, 98 patients were selected for this study. The selected patients were non-diabetic prior to the operation and had undergone follow-up tests for glucose metabolism and an abdominal computed tomography (CT) scan 1 year after the operation. The clinical data of these patients were retrospectively analyzed by reviewing the medical records, radiologic images, and pathologic reports. Results: Postoperative pathology confirmed malignant tumors in 91 patients, borderline malignancy in 5, and benign tumor in 2. The tumor locations included the pancreatic head (n=30), the common bile duct (CBD) (n=30), ampulla of Vater (n=30), and the duodenum (n=8). New-onset DM occurred in 17 (17.4%) of the 98 patients during the first year after the operation. The comparative analysis between postoperative DM (+) and DM (−) groups revealed that the atrophy of the remaining pancreas was the only significant risk factor for development of postoperative DM after PD. Conclusions: This study suggests that the atrophy of the remaining pancreas increases the risk of pancreatogenic DM after PD, and efforts to prevent pancreatic atrophy are needed to decrease this complication. (Korean J Hepatobiliary Pancreat Surg 2012;16:167-171)

Key Words: Pancreatectoduodenectomy; Pancreatogenic diabetes mellitus; Pancreatic atrophy

INTRODUCTION

There is limited data on the long-term quality of life of the patients following the pancreaticoduodenectomy (PD), mainly due to the poor prognosis of the malignant disease constituting the major indications for this operative procedure, along with the high postoperative morbidity and mortality rates. However, the long-term survival rate has recently increased due to the refined surgical techniques, improvement in perioperative management, development of adjuvant treatments, and more frequent use of PD in benign and borderline malignant tumors. The improved survival after PD has led to an increased concern regarding the long-term metabolic consequences.

The loss of pancreatic parenchyma resulting from pancreaticoduodenectomy can lead to the abnormality in the glucose homeostasis known as pancreatogenic diabetes mellitus (DM). Impairment of the glucose metabolism after PD is difficult to predict and can range from minimal to major metabolic derangements. Although pancreatic insufficiency is generally known to occur when more than 80% of the pancreas is resected, new-onset DM has been reported to develop in 20-50% of the patients even after PD involving the removal of approximately 40-50% of pancreatic volume. Pancreatogenic DM can compromise the long-term quality of life of the patients, because it is frequently associated with iatrogenic hypoglycemia resulting from increased peripheral sensitivity to insulin, unlike other types of DM; hence, it is difficult to control with medication. Long-term inadequate glycemic control can also cause nephropathy, neuropathy, and retinopathy.
Therefore, it is important to evaluate the incidence of pancreatogenic DM after PD, and identify the risk factors of developing this complication. Previous studies on pancreatogenic DM mainly examined the changes in hormone secretion or glucose metabolism after pancreatectomy.\textsuperscript{2,5} There have been few clinical studies which have aimed to identify the risk factors associated with pancreatogenic DM.\textsuperscript{6} In this study, we investigated the frequency of occurrence of new-onset pancreatogenic DM after PD, and analyzed the risk factors associated with the complication.

**METHODS**

**Patients**

The PD was performed in 170 patients between November 2003 and September 2009. Among those patients, 98 patients who had undergone follow-up tests for glucose metabolism at one year after the surgery were selected for this study. Among the patients, 48 patients with underlying DM and 24 patients who were lost to follow-up or died within one year after the operation were excluded from the study. The patients were divided into two groups, according to the postoperative development of DM; DM (+) group (n=17) and DM (−) group (n=81). The clinical data of these patients were retrospectively analyzed by reviewing the medical records, radiologic images, and pathologic reports. To identify the risk factors for new-onset DM after PD, the following data were compared between the two groups: age, sex, body mass index (BMI), type of operation (Whipple vs. pylorus-preserving pancreateoduodenectomy [PPPD]), tumor site, pathologic diagnosis (benign or borderline malignancy vs. malignancy), T stage, N stage, amount of intraoperative blood loss, operation time, postoperative complication, postoperative hospital stay, size of postoperative pancreatic duct, underlying pancreatitis, postoperative atrophy of the remaining pancreas, history of adjuvant chemoradiation therapy, and recurrence.

**Definition of parameters**

All patients underwent glucose metabolism tests, including oral glucose tolerance test (OGTT), as well as an abdominal computed tomography (CT), before and one year after the operation. In the OGTT, the blood glucose was measured after fasting and two hours after drinking a glucose-rich beverage. Pancreatogenic DM was defined as the presence of diabetes symptoms, a random glucose level >200 mg/dl, fasting blood sugar (FBS) >126 mg/dl, or postprandial glucose level >140 mg/dl. The pancreatic duct was defined to be dilated when it was five mm or more in diameter on the postoperative CT images. The thickness of the pancreatic parenchyma near the pancreaticoenteric anastomosis site was measured using an abdominal CT, before and one year after the operation. Pancreatic atrophy was confirmed when the postoperative parenchymal thickness was reduced to <50% of the preoperative value. The presence of pancreatitis was evaluated by postoperative pathologic examination.

**Statistics**

In order to determine the risk factors for development of diabetes, the categorical variables were compared using chi-square test, and the continuous variables were compared using the non-parametric Mann-Whitney U test. All the statistical analysis was performed using the SPSS version 19.0 for Windows (SPSS Inc., Chicago, IL, USA). A \( p \)-value less than 0.05 was considered statistically significant.

**RESULTS**

**Demographic characteristics**

The demographic characteristics of the study population were summarized in Table 1. The study included 61 male and 37 female patients, with a mean age of 66.2 years (range: 18-78 years). Twenty-three patients (23.5%) had BMI of 25 or more. The tumor locations included the pancreatic head (n=30, 30.6%), the common bile duct (n=30, 30.6%), ampulla of Vater (n=30, 30.6%), and the duodenum (n=8, 8.2%). PPPD was performed in 86 patients (87.8%) and the Whipple procedure in 12 patients (12.2%). Postoperative pathology confirmed: malignancy in 91 patients (adenocarcinoma, ductal adenocarcinoma, signet ring cell carcinoma, acinar cell carcinoma, metastatic renal cell carcinoma, and undifferentiated carcinoma with osteoclast-like giant cells); borderline malignancy in five patients (intraductal papillary mucinous adenoma [IPMN] with low/high grade dysplasia); and benign disease (serous microcystic adenoma, and well differentiated endocrine tumor) in two patients. Postoperative complica-
Table 1. Demographic characteristics of the patients

| Age (mean±SD, years) | 66.2±11.8 |
|----------------------|-----------|
| Sex                  |           |
| Male                 | 61 (62.3%)|
| Female               | 37 (37.7%)|
| BMI (kg/m²)          |           |
| <25                  | 75 (76.5%)|
| ≥25                  | 23 (23.5%)|
| Location             |           |
| Pancreas             | 30 (30.6%)|
| Common bile duct     | 30 (30.6%)|
| Duodenum             | 8 (8.2%)  |
| Ampulla of Vater     | 30 (30.6%)|
| Pathologic diagnosis |           |
| Malignancy           | 91        |
| Borderline malignancy| 5         |
| Benign               | 2         |
| Type of operation    |           |
| PPPD                 | 86 (87.8%)|
| Whipple              | 12 (12.2%)|
| Postoperative hospital stay (days) | 25.5±7.5 |
| T staging            |           |
| T1                   | 37        |
| T2                   | 25        |
| T3                   | 23        |
| T4                   | 13        |
| N staging            |           |
| N0                   | 51        |
| N1                   | 47        |
| Postoperative complication | 40 (40.8%) |
| Pancreatic fistula   | 17        |
| Wound complication   | 6         |
| Intraabdominal fluid collection | 4 |
| Bleeding complication| 4         |
| Delayed gastric emptying | 4 |
| Others (ileus, pneumonia, pleural effusion, and voiding difficulty) | 5 |

BMI, body mass index; PPPD, pylorus-preserving pancreateoduodenectomy

Risk factors for postoperative DM

In the follow-up of one year after the operation, postoperative new-onset DM (NODM) had developed in 17 (17.4%) of the 98 patients. Table 2 shows the comparative analysis of the risk factors for postoperative DM after PD two. Age, sex, BMI, type of operation, tumor site, pathology diagnosis, T stage, N stage, amount of intraoperative blood loss, operation time, postoperative complication, postoperative hospital stay, postoperative pancreatic-duct size, underlying pancreatitis, history of adjuvant chemoradiation therapy, and recurrence were not significantly different between the NODM group and no-NODM group. Pancreatic atrophy was found to be the only significant risk factor for the development of postoperative DM after PD, with 10 patients (58.8%) in the NODM group vs. 18 patients (22.2%) in no-NODM group (p=0.004).

DISCUSSION

There have been contradictory reports on the development of pancreatogenic DM after PD. The degree of glucose metabolism impairment after pancreatectomy is related to the extent of pancreatic parenchyma resection, underlying pancreatic disease, and duration of follow-up. Assuming that PD involves the removal of similar volume (approximately 40-50%) of pancreatic parenchyma, the development of DM after PD can be mainly determined by the latter two factors. However, most studies on this subject had variable follow-up durations after the operation or included patients with different endocrine function of the pancreatic parenchyma prior to surgery. Some previous studies with a short-term follow-up suggested that DM was unlikely to develop after PD, while long-term follow-up studies reported the incidence of postoperative DM ranging from 20-50%. In addition, many studies included patients with underlying chronic pancreatitis or preoperative DM, making it difficult to determine the effect of PD on the glucose metabolism of the remaining pancreatic parenchyma. To control the possible bias, this study was designed with patients who were non-diabetic preoperatively, with the evaluation of their glucose metabolism function at the same time-interval after operation. The results show that NODM occurred in 17% of the non-diabetic patients who underwent PD during the follow-up of one year after the operation. This is consistent with the results of the previous studies that reported the incidence rate of 9-20% of pancreatogenic diabetes after PD. This finding indicates that the impairment of pancreatic endocrine function may develop after some degree of resection, unlike the exocrine function that may not be hampered even after the
Table 2. Comparison of clinicopathologic factors between new-onset diabetes mellitus (NODM) group and no-NODM group

|                          | NODM group | No NODM group | p-value |
|--------------------------|------------|---------------|---------|
| Age, mean (years)        | 67±14.5    | 65±15.2       | 0.314   |
| Male                     | 12         | 49            | 0.391   |
| Female                   | 5          | 32            |         |
| Intraoperative blood loss (ml) | 782±322   | 815±575       | 0.902   |
| Length of stay (days)    | 28.5±3.2   | 21.9±4.1      | 0.234   |
| Operation time (minutes) | 420±82     | 436±78        | 0.532   |
| Operation name           |            |               | 0.648   |
| PPPD                     | 14         | 72            |         |
| Whipple                  | 3          | 9             |         |
| Cancer site              |            |               |         |
| Pancreas                 | 7          | 23            | 0.623   |
| Common bile duct         | 7          | 23            | 0.395   |
| Duodenum                 | 0          | 8             | 0.999   |
| Ampulla of Vater         | 3          | 27            | 0.188   |
| Transfusion              |            |               | 0.969   |
| Yes                      | 12         | 61            |         |
| No                       | 5          | 20            |         |
| BMI                      |            |               | 0.301   |
| <25                      | 14         | 61            |         |
| ≥25                      | 3          | 20            |         |
| Postoperative complication|           |               | 0.770   |
| Yes                      | 6          | 34            |         |
| No                       | 11         | 47            |         |
| Postoperative pancreatic duct dilatation |            |               | 0.085   |
| Yes                      | 11         | 45            |         |
| No                       | 6          | 36            |         |
| Pancreatitis             |            |               | 0.824   |
| Yes                      | 4          | 25            |         |
| No                       | 13         | 56            |         |
| Pancreatic atrophy       |            |               | 0.004   |
| Yes                      | 10         | 18            |         |
| No                       | 7          | 63            |         |
| Adjuvant therapy         |            |               | 0.402   |
| Yes                      | 4          | 25            |         |
| No                       | 13         | 56            |         |
| T staging                |            |               | 0.457   |
| T1/T2                    | 12         | 50            |         |
| T3/T4                    | 5          | 31            |         |
| N staging                |            |               | 0.332   |
| N0                       | 9          | 42            |         |
| N1                       | 8          | 39            |         |
| Recurrence               |            |               | 0.245   |
| Yes                      | 5          | 32            |         |
| No                       | 12         | 49            |         |

BMI, body mass index; PPPD, pylorus-preserving pancreateoduodenectomy

Therefore, the endocrine function of patients with a long life expectancy after PD should be carefully monitored in order to early detect diabetes and to avoid the long-term complications caused by inadequate glycemic control.

Another important finding of this study is that among various clinicopathologic factors, postoperative pancreatic atrophy was the only risk factor for pancreatogenic DM after PD. The pancreatic atrophy after pancreatic head resection resulted in the loss of endocrine function of pancreas.9 This finding is contradictory to the previous study of You et al.3 which showed that the volume of the remnant pancreas was not associated with pancreatogenic diabetes. These inconsistent results can be explained by the differences in the study design. The study of You et al.3 included 55 patients who had survived, after a median follow-up duration of no less than 55 months, among the 168 patients who had undergone PD; and the results of pancreatic endocrine function of the remaining patients were not presented. In comparison, this study evaluated the pancreatic endocrine function of all patients who had the follow-up period of more than one year. As such, the selection bias cannot be excluded in the previous study of You et al. Nonetheless, considering the small number of patients in this study, further prospective studies with a larger number of patients are needed to clarify the effects of pancreatic atrophy on pancreatogenic DM after PD.

Atrophy of the remnant distal pancreas after PD commonly occurs, and there have been several animal and human studies in the attempts of preventing the pancreas atrophy.9 Although the mechanism is not well elucidated, a suggested mechanism involves the loss of gastrointestinal hormones with the trophic effect on the pancreas, such as cholecystokinin and gastrin, resulting from the resection of the duodenum and the distal stomach. Jang et al. reported that induced hypergastrinemia can prevent pancreatic atrophy after PPPD, likely via a mechanism of the regenerative activity of the pancreas stimulated by gastrin.9 Additionally, a recent animal study showed that control of serum glucose levels play an important role in preventing pancreatic atrophy.10 Based on the result of these studies, the efforts to prevent pancreatic atrophy should be continued and clinically applied to de-
crease the incidence of pancreatogenic DM after PD.

In conclusion, this study suggests that pancreatogenic DM is not an uncommon complication after PD, and that postoperative atrophy of the remaining pancreas significantly increases the risks of this complication. As such, patients who undergo PD need to be carefully followed up, in order to monitor the glucose metabolism function in avoiding the DM related long-term complications and improving their quality of life. In addition, various efforts to prevent the atrophy of the remaining pancreas are required to decrease this complication.

REFERENCES

1. Huang JJ, Yeo CJ, Sohn TA, et al. Quality of life and outcomes after pancreaticoduodenectomy. Ann Surg 2000;231:890-898.
2. Slezak LA, Andersen DK. Pancreatic resection: effects on glucose metabolism. World J Surg 2001;25:452-460.
3. You DD, Choi SH, Choi DW, et al. Long-term effects of pancreaticoduodenectomy on glucose metabolism. ANZ J Surg 2012;82:447-451.
4. Falconi M, Mantovani W, Crippa S, et al. Pancreatic insufficiency after different resections for benign tumours. Br J Surg 2008;95:85-91.
5. Ishikawa O, Ohigashi H, Eguchi H, et al. Long-term follow-up of glucose tolerance function after pancreaticoduodenectomy: Comparison between pancreaticogastrostomy and pancreatecojejunostomy. Surgery 2004;136:617-623.
6. Lemaire E, O’Toole D, Sauvanet A, et al. Functional and morphological changes in the pancreatic remnant following pancreaticoduodenectomy with pancreaticogastric anastomosis. Br J Surg 2000;87:434-438.
7. Park YC, Kim SW, Jang JY, et al. Factor influencing delayed gastric emptying after pylorus-preserving pancreaticoduodenectomy. J Am Coll Surg 2003;196:859-865.
8. Bock EA, Hurtuk MG, Shoup M, et al. Late complication after pancreaticoduodenectomy with pancreaticogastrostomy. J Gastrointest Surg 2012;16:914-919.
9. Jang JY, Kim SW, Han JK, et al. Randomized prospective trial of the effect of induced hypergastrinemia on the Prevention of pancreatic atrophy after pancreaticoduodenectomy in humans. Ann Surg 2003;237:522-529.
10. Yamamoto M, Jia DM, Fukumitsu K, Otsuki M. Treatment for hyperglycemia promotes pancreatic regeneration in rats without CCK-1 receptor gene expression. Pancreas 2003;26:368-374.
11. Jang JY, Kim SW, Park SJ, et al. Comparison of the functional outcome after pylorus-preserving pancreaticoduodenectomy: pancreatogastrostomy and pancreatecojejunostomy. World J Surg 2002;26:366-371.
12. Maeda H, Hanazaki K. Pancreatogenic diabetes after pancreatic resection. Pancreatology 2011;11:268-276.
13. Kim SW, Kim KW, Han JK, et al. Pylorus-preservation decreases the extent of atrophy of the remnant pancreas after pancreaticoduodenectomy. HPB 1999;1:65-70.
14. McPhee JT, Hill JS, Giles FW, et al. Perioperative mortality for pancreatogastrostomy: a national perspective. Ann Surg 2007;246:246-253.
15. Permert K, Ihs E, Jorgedt L, et al. Improved glucose metabolism after subtotal pancreaticojejunostomy for pancreatic cancer. Br J Surg 1993;80:1047-1050.
16. Izbicki JR, Bloechle C, Knoefel WT, et al. Duodenum-preserving resection of the head of the pancreas in chronic pancreatitis: a prospective randomized trial. Ann Surg 1995;221:350-358.
17. Büchler M, Friess H, Muller M, et al. Randomized trial of duodenumpreserving pancreatic head resection versus pylorus-preserving Whipple in chronic pancreatitis. Am J Surg 1995;169:65-69.
18. Grigore C, Sarbu V, Simion S, et al. Pancreatogenic diabetes patient selection for pancreatic islet transplantation. J Med Life 2010;3:84-89.
19. King J, Kazanjian K, Matusumoto J, et al. Distal Pancreatectomy: Incidence of postoperative diabetes. J Gastrointest Surg 2008;12:1548-1553.